Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Global Operations President Hanspeter Spek On Building A Diversified Strategy In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

In an interview in Shanghai, the senior Sanofi exec talks about the company’s diversified strategy in emerging markets, affordability issues and the French pharma’s partnering aspirations in China.

You may also be interested in...



More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity

HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups

Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 2 of 2)

Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.

With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics

SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel